John Breton

Geological Society of London — United Kingdom

Medicine · Health Sciences

18h-index1.7kcitations43works9.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory mediators and NSAID effects(8), Urinary Tract Infections Management(8), Asthma and respiratory diseases(4), Pediatric Urology and Nephrology Studies(4), Natural product bioactivities and synthesis(4)

Publications43 total

Efficacy and <i>in vitro</i> activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3)
Antimicrobial Agents and Chemotherapy·2025Open Access
Efficacy and <i>in vitro</i> activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3)
Antimicrobial Agents and Chemotherapy·2025· 2 citedOpen Access
Plain language summary: efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infection
Future Microbiology·2025· 3 citedOpen Access
512. Efficacy of Gepotidacin versus Nitrofurantoin in a Nitrofurantoin Not Susceptible Population: A Pooled Analysis of the EAGLE-2 and EAGLE-3 Randomized Controlled Trials in Uncomplicated Urinary Tract Infection
Open Forum Infectious Diseases·2025Open Access
P-1101. A Comparative Analysis of Resistance Rates Among <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates Collected from the Gepotidacin Uropathogen Global Surveillance Studies and Phase 3 Uncomplicated Urinary Tract Infection Clinical Studies
Open Forum Infectious Diseases·2025Open Access
P-1492. Patient Characteristics Associated with Extended-Spectrum Beta-Lactamase-Producing Uropathogens: Pooled Results from Two Phase 3 Clinical Trials of Gepotidacin for the Treatment of Uncomplicated Urinary Tract Infection
Open Forum Infectious Diseases·2025Open Access
Efficacité du liraglutide intra-articulaire, analogue de GLP-1, sur les paramètres inflammatoires et structuraux dans un modèle d’arthrose : étude comparative avec la dexaméthasone
Revue du Rhumatisme·2024
Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials
The Lancet·2024· 67 cited
Ochronosis and lumbar disc herniation - A case report and literature review
Interdisciplinary Neurosurgery·2023· 1 citedOpen Access
P31 Efficacy and safety of oral gepotidacin in the treatment of uncomplicated urinary tract infection: results of two randomized, multicentre Phase 3 trials (EAGLE-2 and EAGLE-3)
JAC-Antimicrobial Resistance·2023· 2 citedOpen Access
Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis
Scientific Reports·2022· 115 citedOpen Access
Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
Journal of Orthopaedic Translation·2022· 79 citedOpen Access
Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial
The Lancet Child & Adolescent Health·2021· 15 cited
THU0055 ANTI-DEGRADATIVE AND PRO-CHONDROGENIC PROPERTIES OF LIRAGLUTIDE, A GLUCAGON-LIKE-PEPTIDE 1 RECEPTOR AGONIST: EVIDENCE FROM PRECLINICAL STUDIES AND IMPLICATION FOR OSTEOARTHRITIS
Annals of the Rheumatic Diseases·2020· 3 cited
Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria
Pharmacogenetics and Genomics·2020· 13 citedOpen Access
Single-Dose Tafenoquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria
New England Journal of Medicine·2019· 277 citedOpen Access
Tafenoquine versus Primaquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria
New England Journal of Medicine·2019· 239 citedOpen Access
A Randomized, Double-blind, Comparative Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment 1% Versus Oral Linezolid in the Treatment of Secondarily Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus aureus
Advances in Skin & Wound Care·2014· 15 cited
The Safety and Efficacy of Topical Retapamulin Ointment Versus Placebo Ointment in the Treatment of Secondarily Infected Traumatic Lesions
Advances in Skin & Wound Care·2013· 8 cited
Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: Results of a randomized controlled trial
Journal of the American Academy of Dermatology·2006· 71 cited
page 1 of 3Next →

Frequent Co-authors

Marie Chabot‐Fletcher(17), Nicole E. Scangarella-Oman(10), Don E. Griswold(8), Amanda Sheets(8), Deborah Butler(7), Jerry L. Adams(6), Jeremy Dennison(6), Salim Janmohamed(6), Ravi S. Garigipati(5), Margaret E. Sorenson(5), Edward F. Webb(5), Caroline Perry(5), Helen Millns(5), Stephan Duparc(4), Justin A. Green(4), Leonard M. Hillegass(4), C. Meurot(4), Révital Rattenbach(4), Florian Wagenlehner(4), Marcus Lacerda(3)